Please login to the form below

SCLC

This page shows the latest SCLC news and features for those working in and with pharma, biotech and healthcare.

alone in extensive-stage small cell lung cancer (ES-SCLC).

AZ’s Imfinzi gets US OK in small cell lung cancer, challenging Tecentriq

which is more common than SCLC – as well as bladder cancer and triple-negative breast cancer. ... Keytruda already has approval for third-line SCLC treatment after the failure of chemotherapy and has a phase 3 trial as a first-line treatment nearing
AZ’s Imfinzi plus tremelimumab combo misses again

AZ notes the CTLA4 inhibitor remains in clinical trials in combination with Imfinzi in NSCLC, SCLC, bladder cancer, head and neck cancer and liver cancer. ... SCLC last year and is still the only checkpoint inhibitor licensed for this use.
Roche’s PD-L1 inhibitor Tecentriq approved in China for SCLC

months in SCLC patients, compared to 10.3 months in the placebo group. ... SCLC accounts for around 15% of all lung cancer cases, with two-thirds of those diagnosed at the extensive stage of the disease.
AZ’s Imfinzi scores orphan drug status in liver cancer

If approved, it will go on to directly compete with Roche’s Tecentriq, which is already approved in first-line SCLC.
Keytruda doesn’t extend survival in small cell lung cancer

use of the drug into first-line therapy for extensive-stage small cell lung cancer (SCLC). ... The trial enrolled 453 patients with newly diagnosed extensive-stage SCLC, who were randomly assigned to either Keytruda or placebo on top of standard

More from news
Approximately 5 fully matching, plus 28 partially matching documents found.

Deal Watch February 2017

triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. .
Deal Watch April 2016

Rova-T showed a 44% overall response rate in DLL-expressing small cell lung cancer (SCLC) patients who had failed one or more standard therapies.
Deal Watch November 2015

July finalised a $730m exclusive deal with Boehringer Ingelheim for HM61713, an orally active third generation EGFR agent in small cell lung cancer (SCLC).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Add my company

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

The big issue: Whether you want to lead or follow, you need to understand the elephant in the C-suite...
INFOGRAPHIC 02: The Importance of clinical study websites: Here’s a infographic of why clinical study websites are important to patient recruitment and retention strategies…...
Working with, Advocating for, and Empowering Patients: A holistic view of how to work with patients virtually...